Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board

PURPOSE: In 2016, the University of Munich Molecular Tumor Board (MTB) was implemented to initiate a precision oncology program. This review of cases was conducted to assess clinical implications and functionality of the program, to identify current limitations and to inform future directions of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinrich, Kathrin, Miller-Phillips, Lisa, Ziemann, Frank, Hasselmann, Korbinian, Rühlmann, Katharina, Flach, Madeleine, Biro, Dorottya, von Bergwelt-Baildon, Michael, Holch, Julian, Herold, Tobias, von Baumgarten, Louisa, Greif, Philipp A., Jeremias, Irmela, Wuerstlein, Rachel, Casuscelli, Jozefina, Spitzweg, Christine, Seidensticker, Max, Renz, Bernhard, Corradini, Stefanie, Baumeister, Philipp, Goni, Elisabetta, Tufman, Amanda, Jung, Andreas, Kumbrink, Jörg, Kirchner, Thomas, Klauschen, Frederick, Metzeler, Klaus H., Heinemann, Volker, Westphalen, C. Benedikt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261163/
https://www.ncbi.nlm.nih.gov/pubmed/35796778
http://dx.doi.org/10.1007/s00432-022-04165-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261163/
https://www.ncbi.nlm.nih.gov/pubmed/35796778
http://dx.doi.org/10.1007/s00432-022-04165-0

Ejemplares similares